Effects of pulsed electromagnetic fields on the expression of NFATc1 and CAII in mouse osteoclast-like cells

Aging Clinical and Experimental Research

Volumn 27, Issue 1, 2015, Pages 13-19

  He, Jianquan ^a   Zhang, Yongsheng ^a   Chen, Jian ^a   Zheng, Suyu ^a   Huang, Hui ^a   Dong, Xiaoyu ^a  

^a ZHONGSHAN HOSPITAL OF XIAMEN UNIVERSITY   (China)

Author keywords

CAII mRNA; NFATc1mRNA; Osteoclast like cells; Pulsed electromagnetic fields; RANK mRNA

Indexed keywords

CARBONATE DEHYDRATASE II; COLONY STIMULATING FACTOR 1; MESSENGER RNA; NFATC1 PROTEIN, MOUSE; OSTEOCLAST DIFFERENTIATION FACTOR; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TNFRSF11A PROTEIN, MOUSE; TNFSF11 PROTEIN, MOUSE; TRANSCRIPTION FACTOR NFAT;

ANIMAL; C57BL MOUSE; ELECTROMAGNETIC FIELD; FEMALE; GENETICS; METABOLISM; MOUSE; OSTEOCLAST;

ANIMALS; CARBONIC ANHYDRASE II; ELECTROMAGNETIC FIELDS; FEMALE; MACROPHAGE COLONY-STIMULATING FACTOR; MICE; MICE, INBRED C57BL; NFATC TRANSCRIPTION FACTORS; OSTEOCLASTS; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RNA, MESSENGER;

EID: 84939877229     PISSN: 15940667     EISSN: 17208319     Source Type: Journal    
DOI: 10.1007/s40520-014-0239-6     Document Type: Article

References (37)

1. Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster JY (2013) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 24:23–57. doi:10.1007/s00198-012-2074-y
2. Lewiecki EM (2010) Treatment of osteoporosis with denosumab. J Maturitas 66:182–186. doi:10.1016/j.maturitas.2010.02.008
3. Lacey DL, Timms E, Tan HL et al (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. J Cell 93:165–176. doi:10.1016/S0092-8674(00)81569-X
4. Hofbauer LC, khosla S, Dunstan CR et al (2000) The roles of osteoprotegerin:a novel secreted osteoprotegerin ligand in the regulation in the paracrine regulation of bone resorption. J Bone Miner Res 15:2–12. doi:10.1359/jbmr.2000.15.1.2
5. Vega D, Maalouf NM, Sakhaee K (2007) The role of receptor activator of nuclearfactor-κB (RANK)/RANK ligand/osteoprotegerin:clinical implications. J Clin Endocrinol Metabol 92:4514–4521. doi:10.1210/jc.2007-0646
6. Hadjidakis DJ, Androulakis II (2006) Bone remodeling. J Ann NY Acad Sci 1092:385–396. doi:10.1196/annals.1365.035
7. Takayanagi H, Kim S, Koga T et al (2002) Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. J Dev Cell 3:889–901. doi:10.1016/S1534-5807(02)00369-6
8. Takayanagi H (2005) Mechanistic insight into osteoclast differentiation in osteoimmunology. J Mol Med 83:170–179. doi:10.1007/s00109-004-0612-6
9. Asagiri M, Sato K, Usami T et al (2005) Autoamplification of NFATc1 expression determines its essential role in bone homeostasis. J Exp Med 202:1261–1269. doi:10.1084/jem.20051150
10. Zelzer E, Olsen BR (2003) The genetic basis for skeletal diseases. J Nature 23:343–348. doi:10.1038/nature01659
11. Mostov K, Werb Z (1997) Journey across the osteoclast. J Sci 276:219–220. doi:10.1126/science.276.5310.219
12. Teitelbaum SL (2000) Bone resorption by osteoclasts. J Sci 289:1504–1508. doi:10.1126/science.289.5484.1504
13. SatterSyed A, Islam MS, Rabbani KS, Talukder MS (1999) Pulsed electromagnetic fields for the treatment of bone fractures. J Bangladesh Med Res Counc Bull 25:6–10
14. Nicolakis P, Kollmitzer J, Crevenna R et al (2002) Pulsed magnetic field therapy for osteoarthritis of the knee-a double-blind sham-controlled trial. J Wien Klin Wochenschr 114:678–684
15. Garland DE, Adkins RH, Matsuno NN, Stewart CA (1999) The Effect of pulsed electromagnetic fields on osteoporosis at the knee in Individuals with spinal cord injury. J Spinal Cord Med 22:239–245
16. Jing D, Shen G, Huang J et al (2010) Circadian rhythm affects the preventive role of pulsed electromagnetic fields on ovariectomy-induced osteoporosis in rats. J Bone 46:487–495. doi:10.1016/j.bone.2009.09.021
17. Chen J, He H-C, Xia Q-J et al (2010) Effects of pulsed electromagnetic fields on the mRNA expression of RANK and CAII in ovariectomized Rat osteoclast-like cells. J Connective Tissue Res 51:1–7. doi:10.3109/03008200902855917
18. Tabrah FL, Ross P, Hoffmeier M, Gilbert FJr (1998) Clinical report on long-term bone density after short-term EMF application. J Bioelectromagnetics 19: 75–78. doi: 10.1002/(SICI)1521-186X(1998)19:2<75::AID-BEM3>3.0.CO;2-0
19. Tabrah F, Hoffmeier M, Gilbert F Jr, Batkin S, Bassett CA (1990) Bone density changes in osteoporosis-prone women exposed to pulsed electromagnetic fields (PEMFs). J Bone Miner Res 5:437–442. doi:10.1002/jbmr.5650050504
20. Pavlos NJ, Xu JK, Riedel D et al (2005) Rab3D regulates a novel vesicular trafficking pathway that is required for osteoclastic bone resorption. Mol J Cell Bio 125:5253–5269. doi:10.1128/MCB.25.12.5253-5269.2005
21. Chen J, He JQ, Zhen SY, Huang L (2012) OPG inhibits gene expression of RANK and CAII in mouse osteoclast-like cells. J Rheumatol Int 32:3393–3398. doi:10.1007/s00296-011-2338-4
22. −ΔΔCt method. J Methods 25:402–408. doi:10.1006/meth.2001.1262
23. Bell NH (2003) RANK ligand and the regulation of skeletal remodeling. J Clin Invest 111:1120–1122. doi:10.1172/JCI18358
24. Boyce BF, Xing L (2008) Functions of RANKL/RANK/OPG in bone modeling and remodeling. J Arch Biochem Biophys 473:139–146. doi:10.1016/j.abb.2008.03.018
25. Grimaud E, Soubigou L, Couillaud S et al (2003) Receptor activator of nuclear factor kappa-B ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis. Am J Path 163:2021–2031. doi:10.1016/S0002-9440(10)63560-2
26. Asagiri M, Takayanagi H (2007) The molecular understanding of osteoclast differentiation. J Bone 40:251–264. doi:10.1016/j.bone.2006.09.023
27. Ishida N, Hayashi K, Hoshijima M et al (2002) Large scale gene expression analysis of osteoclastogenesis in vitro and elucidation of NFAT2 as a key regulator. J Biol Chem 277:41147–41156. doi:10.1074/jbc.M205063200
28. Takayanagi H (2007) The role of NFAT in osteoclast formation. J Annals NY Acad Sci 1116:227–237. doi:10.1196/annals.1402.071
29. Kanis JA, Gluer CC (2001) An update on the diagnosis and assessment of osteoporosis with densitometry. J Osteoporos Int 11:192–202. doi:10.1007/s001980050281
30. Markov MS (2007) Pulsed electromagnetic field therapy history, state of the art and future. Environmental 27:465–475. doi:10.1007/s10669-007-9128-2
31. Ibiwoye MO, Powell KA, Grabiner MD (2004) Bone mass is preserved in a critical-sized osteotomy by low energy pulsed electromagnetic fields as quantitated by in vivo micro-computed tomography. J Orthop Res 22:1086–1093. doi:10.1016/j.orthres.2003.12.017
32. Sert C, Mustafa D, Düz MZ, Aksen F, Kaya A (2002) The preventive effect on bone loss of 50 Hz, 1 mT electromagnetic field in ovariectomized rats. J Bone Miner Metab 20:345–349. doi:10.1007/s007740200050
33. Chang K, Chang WH (2003) Pulsed electromagnetic fields prevent osteoporosis in an ovariectomized female rat model:aprostagl and in E2-associated process. J Bioelectromagnet 24:189–198. doi:10.1002/bem.10078
34. Huang L, Wang W, Xiao D, Yang L, Lei Z, He C (2008) Effect of pulsed electromagnetic fields of different treatment time on bone mineral density of femur in ovariectomized rats. Zhong Guo Xiu Fu Chong Jian Wai Ke Za Zhi 22:548–550
35. Yang YH, He CQ, Yang L, Wang W, Lei ZJ (2008) Effects of different intensity pulsed electromagnetic fields on serum estradiol of ovariectomized rats. Sichuan Da Xue Xue Bao Yi Xue Ban 39:256–258
36. Yang L, Lei Z, He C (2006) Clinical observation of low frequency pulse electromagnetic field on treatment of osteoporosis. J Chin J Osteoporos 12:24–25. doi:10.3969/j.issn.1006-7108.2006.06.013
37. Luo QL, Li S-S, He C, He HC, Yang L, Deng L (2009) Pulse electromagnetic fields effects on serum E2 levels, chondrocyte apoptosis, and matrix metalloproteinase-13 expression in ovariectomized rats. J Rheumatol Int 29:927–935. doi:10.1007/s00296-008-0782-6